Genovis signs agreement on projects for major pharmaceutical company

The one-year development project agreement on behalf of a customer is worth about USD 100,000. The project will adapt Genovis’ products from the protein characterization portfolio to the customer’s technology platform.

“We look forward to launching this initiative together with our customer. This project demonstrates the interest in Genovis’ unique products and is a recognition of our skills and experience in characterizing antibody-based drugs,” says Sarah Fredriksson, CEO of Genovis. 

For more information, please contact: Sarah Fredriksson, CEO, Genovis AB 

T: +46 (0)46-10 12 35 E: sarah.fredriksson@genovis.com

ABOUT GENOVIS

Genovis’ business concept is to develop, produce and market innovative technologies that facilitate and enable development of new treatment methods and diagnostics for customers in the medical device and pharmaceutical industries. The Group consists of Genovis AB and the subsidiary GeccoDots AB. Genovis develops and sells unique enzymes (protein engineering portfolio) in innovative product formats that facilitate development and quality control of and biological drugs. GeccoDots uses nanotechnology to produce a new type of contrast agent that is used in medical imaging.

Genovis shares are listed on NASDAQ OMX First North, and Thenberg Fondkommission is Certified Adviser for the Company, t: +46 (0)31-745 50 00